Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 4/2017

25.08.2017 | Review Article

Management of Borderline Ovarian Tumors—Still a Gray Zone

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Borderline ovarian tumors (BOTs) are a heterogeneous group of non-invasive epithelial ovarian tumors that occur at a younger age, present in early stage, frequently associated with infertility but are easily curable. Although they may have symptomatic long-term recurrences, they have an excellent prognosis in spite of peritoneal spread. Among the epithelial tumors of the ovary, BOTs fall in the spectrum lying between cystadenomas (benign) and cystadenocarcinomas (malignant). Their oncological behavior is more aggressive than benign ovarian tumors but relatively less than that of malignant ovarian tumors. Since the age group affected is usually young females, preservation of fertility is an important aspect of treatment protocol. Although the management of these tumors has been extensively discussed, it still remains a controversial gray zone. In this review, epidemiology, pathogenesis, histologic subtypes, various surgical approaches, follow-up, and management of recurrence have been discussed. Choosing the best treatment still poses a challenge for the treating oncosurgeon.
Literatur
1.
Skirnisdottir I, Garmo H, Wilander E, Holmberg L (2008) Borderline ovarian tumours in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 123:1897–1901CrossRefPubMed
2.
Taylor HC (1929) Malignant and semi-malignant tumours of the ovary. Surg Gynecol Obstet 48:204–230
3.
Scully RE, Young RH, Clement PB (1998) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of Tumor Pathology. 3rd Series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology 1–168
4.
Sherman ME, Berman J, Birrer MJ et al (2004) Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol 35:961–970CrossRefPubMed
5.
Sherman ME, Mink PJ, Curtis R et al (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100:1045–1052CrossRefPubMed
6.
Riman T, Dickman PW, Nilsson S (2001) Risk factors for epithelial borderline ovarian tumours : results of a Swedish case control study. Gynecol Oncol 83:575–585CrossRefPubMed
7.
8.
Van Leeuwen FE, Klip H, Mooji TM et al (2011) Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 26:3456–3465CrossRefPubMedPubMedCentral
9.
Seidman JD, Cho KR, Ronett BM et al (2011) Surface epithelial tumours of the ovary. In : Kurman RJ, Ellenson LH, Ronett BM, editors. Blaustein’s Pathology of the Female Genital Tract. 6th ed. New York : Springer Science + Bussiness Medica Pp. 680–772
10.
Fauvet R, Poncelet C, Booccara J, Descamps P, Fondrinier E, Darai E (2005) Fertility after conservative treatment for borderline ovarian tumours: a French multicenter study. Fertil Steril 83:284–290CrossRefPubMed
11.
Stewart LM, Holman CDJ, Finn JC, Preen DB, Hart R (2013) In vitro fertilization is associated with increased risk of borderline ovarian tumours. Gynecol Oncol 129:372–376CrossRefPubMed
12.
Bjorge T, Lie AK, Hovig E et al (2004) BRCA1 mutations in ovarian cancer and borderline tumours in Norway : a nested case-control study. Br J Cancer 91:1829–1834CrossRefPubMedPubMedCentral
13.
Van Calster B, Timmerman D, Bourne T et al (2007) Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum Ca 125. J Natl Cancer Inst 99:1706–1714CrossRefPubMed
14.
Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E (2005) Laparoscopic management of borderline ovarian tumours : results of a French multicenter study. Ann Oncol 16:403–410CrossRefPubMed
15.
Kurman RJ, Visvanathan K, Roden R et al (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198:351–356CrossRefPubMedPubMedCentral
16.
Sieben NL, Oosting J, Flanagan AM et al (2005) Differential gene expression in ovarian tumours reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline ovarian tumours. J Clin Oncol 23:7257–7264CrossRefPubMed
17.
Seong SJ, Kim DH, Kim MK, Song T (2015) Controversies in borderline ovarian tumours. J Gynaecol Oncol 26(4):343CrossRef
18.
du Bois A, Ewald-Riegler N, du Bois O et al (2009) Borderline tumours of the ovary: a systematic review. Geburtshilfe Frauenheilkd 69:807–833CrossRef
19.
Risum S, Hogdall C, Loft A et al (2007) The diagnostic value of PET/CT for primary ovarian cancer : a prospective study. Gynecol Oncol 105:145–149CrossRefPubMed
20.
Kaern J, Trope CG, Abeler VM (1993) A retrospective study of 370 borderline tumours of the ovary treated at Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 71:1810–1820CrossRefPubMed
21.
Yokoyama Y, Moriya T, Takano T et al (2006) Clinical outcomes and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 94:1586–1591CrossRefPubMedPubMedCentral
22.
Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon
23.
Kane A, Uzan C, Rey A et al (2009) Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumours with peritoneal implants. Oncologist 14:591–600CrossRefPubMed
24.
Bell DA, Weinstock MA, Sculy RE (1988) Peritoneal implants of ovarian serous borderline tumours: histologic features and prognosis. Cancer 62:2212–2222CrossRefPubMed
25.
Burks R, Sherman M, Kurman R (1996) Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumours. Am J Surg Pathol 20:1319–1330CrossRefPubMed
26.
Silverberg S (2006) Borderline ovarian tumours: concensus, controversy, and continuing challenges. Pathol Case Rev 11:9–17CrossRef
27.
Ronett BM, Kajdacsy-Balla A, Gilks CB et al (2004) Mucinous borderline ovarian tumours: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 35:949–960CrossRef
28.
Tempfer CB, Polterauer S, Bentz EK (2007) Accuracy of intra-operative frozen section analysis in borderline tumours of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 107:248–252CrossRefPubMed
29.
Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D (2001) Clinical outcomes and fertility after conservative treatment of ovarian borderline tumours. Fertil Steril 75:92–96CrossRefPubMed
30.
Frega A, Coluccia AC, Di Martino G, Catalano A, Milazzo GN, Assorgi C, Manzara F, Romeo GD, Gentile M, Marziani R, Moscarini M (2014) Borderline ovarian tumors, fertility-sparing surgery and pregnancy outcome. Eur Rev Med Pharmacol Sci 18:281–284PubMed
31.
Uzan C, Muller E, Kane A, Rey A, Gouy S, Bendiffallah S, Duvillard P, Fauvet R, Darai E, Morice P (2014) Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol 25:166–171CrossRefPubMed
32.
Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynecol 16:513–527CrossRef
33.
Lesieur B, Kane A, Duvillard P et al (2011) Prognostic value of lymph node involvement in ovarian serous borderline tumours. Am J Obstet Gynecol 204:438.e1–438.e7CrossRef
34.
Carnatte S, Morice P, Thoury A et al (2004) Impact of surgical staging in patients with macroscopic ‘stage I’ ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 40:1842–1849CrossRef
35.
Deffieux X, Morice P, Camette S et al (2005) Results after laparoscopic management of serous borderline tumour of the ovary with peritoneal implants. Gynecol Oncol 97:84–89CrossRefPubMed
36.
Vandenput I, Amant F, Vergote I (2005) Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumours that were treated by laparotomy. Gynecol Oncol 98:523CrossRefPubMed
37.
Shim S-H, Kim S-N, Jung P-S, Dong M, Kim JE, Lee SJ (2016) Impact of surgical staging on prognosis in patients with borderline ovarian tumours: a meta-analysis. Eur J Cancer 54:84–95CrossRefPubMed
38.
Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E (2004) Restaging surgery for women with borderline ovarian tumours: results of a French multicenter study. Cancer 100:1145–1151CrossRefPubMed
39.
Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L et al (2013) Ovarian cancer, version 2.2013. J Natl Copmr Canc Netw 11:1199–1209
40.
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopapoulou C et al (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynaekologische Onkologie (AGO) Study Group. Eur J Cancer 49:1905–1914CrossRefPubMed
41.
Sutton GP, Bundy GN, Omura GA et al (1991) Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy: a gynecologic oncology group study. Gynecol Oncol 41:230–233CrossRefPubMed
42.
Barakat RR, Benjamin IB, Lewis JL Jr et al (1995) Platinum based chemotherapy for advanced stage serous ovarian tumors of low malignant potential. Gynecol Oncol 59:390–393CrossRefPubMed
43.
Ronnett BM, Kurman RJ, Shmookler BM et al (1995) Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 26:509–524CrossRefPubMed
44.
Creasman WT, Park R, Norris H, Disaia PJ, Morrow CP, Hreshchyshyn MM (1982) Stage I borderline ovarian tumors. Obstet Gynecol 59(1):93–96PubMed
45.
Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T (1991) Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 41(3):230–233CrossRefPubMed
46.
Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V (1993) Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. [review] [27 refs]. Gynecol Oncol 51(2):236–243CrossRefPubMed
47.
Barnhill DR, Kurman RJ, Brady MF et al (1995) Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group Study. J Clin Oncol 13:2752–2756CrossRefPubMed
48.
Practice Committee of the American Society for Reproductive Medicine: Society of Reproductive Surgeons (2007) Pathogenesis, consequences and control of peritoneal adhesions in gynecologic surgery. Fertil Steril 88:21–26CrossRef
49.
Fasouliotis SJ, Davis O, Schattman G et al (2004) Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumours: a preliminary report. Fertil Steril 82:568–572CrossRefPubMed
50.
Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A (2006) Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 100:185–191CrossRefPubMed
51.
Kurman RJ, Trimble CL (1993) The behavior of serous tumours of low malignant potential : are they ever malignant? Int J Gynecol Pathol 12:120–127CrossRefPubMed
52.
Silva EG, Gershenson DM, Malpica A et al (2006) The recurrence and the overall survival rates of ovarian serous borderline neoplasms with non-invasive implants is time dependent. Am J Surg Pathol 30:1367–1371CrossRefPubMed
53.
Kaern J, Trope C, Kjorstad KE et al (1990) Cellular DNA content as a new prognostic tool in patients with borderline tumours of the ovary. Gynecol Oncol 38:452–457CrossRefPubMed
54.
Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM et al (2014) Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian tumours of low malignant potential (borderline ovarian tumours). Int J Gynecol Cancer 24:S5–S8CrossRefPubMed
55.
Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N et al (2014) Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgmeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol 25:1320–1327CrossRefPubMed
56.
Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C (2001) Behaviour of borderline tumours with particular interest to persistence, recurrence and progression to invasive carcinoma: a prospective study. J Clin Oncol 19:2658–2664CrossRefPubMed
57.
Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2009) Surgical management of borderline ovarian tumours: the role of fertility-sparing surgery. Gynecol Oncol 113:75–82CrossRefPubMed
58.
Trimble CL, Kosary C, Trimble EL (2002) Long term survival and patterns of care in women with ovarian carcinoma: a population based analysis. Gynecol Oncol 86:34–37CrossRefPubMed
59.
APM H, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. 26th Annual Report on the Results of Treatment in Gynaecological Cancer. Int J Gynaecol Obstet 95(suppl 1):S161–S192
60.
Seidman JD, Kurman RJ (1996) Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20:1331–1345CrossRefPubMed
Metadaten
Titel
Management of Borderline Ovarian Tumors—Still a Gray Zone
Publikationsdatum
25.08.2017
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 4/2017
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-017-0697-3

Weitere Artikel der Ausgabe 4/2017

Indian Journal of Surgical Oncology 4/2017 Zur Ausgabe

Case report

Metachronous Synchronous Sternal and Colonic Metastasis with Asymptomatic Colo-colic Fistula from Carcinoma Ovary Rare Presentation of Ovarian Cancer

Letter to the Editor

Tailoring the Best Technique in the Surgical Management of IVC Thrombosis

Original Article

Radical Treatment of Rectal Cancer in Elderly Is Feasible than Feared: Results from a Tertiary Care Centre

Original Article

Quality of Life After “Total Mesorectal Excision (TME)” for Rectal Carcinoma: a Study from a Tertiary Care Hospital in Northern India

Original Article

Deterministic Role of CEA and MSI Status in Predicting Outcome of CRC Patients: a Perspective Study Amongst Hospital Attending Eastern Indian Populations

Original Article

Ovarian Metastases of Colorectal Origin: Treatment Patterns and Factors Affecting Outcomes

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.